In Spain Supply shortages of medicines used to treat menopausal symptoms are worsening. The Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) has confirmed disruptions to the supply of several products used in hormone replacement therapy for months. This week, Spanish media reported a worsening shortage, forcing numerous patients to change or temporarily interrupt their treatment.
The estradiol spray Lenzettois particularly affected, with its availability repeatedly reported as limited. Transdermal patches such as Estradot and Evopad as well as combination capsules such as Bijuva are also difficult to obtain at times in some regions. Pharmacists and doctors say that increased demand for alternatives is putting further pressure on other formulations in turn.
The AEMPS cites production and supply-chain problems as the main reasons, varying according to the active ingredient and manufacturer. It says that the timing of a return to normal supply nationwide depends on the progress of technical solutions at the companies. The agency also stresses that not all products are affected equally and that doctors can switch patients to available alternatives.
For many people affected, treatment is not a matter of comfort but a medical necessity. It relieves hot flushes, sleep disorders and other perimenopausal symptoms. According to gynaecologist Mercedes Herrero from the practice Gine4 several hundred thousand women in Spain now use hormone replacement therapy; demand has risen. Patients report a lack of short-notice appointments with doctors and say that switching to another product causes uncertainty. This could lead to treatment being interrupted, worsening symptoms.
Experts advise patients not to stop treatment on their own, but to switch to available alternatives in consultation with their healthcare provider. Depending on the individual case, transdermal patches, gels or tablets may be considered. Shortages can be particularly difficult for women with specific indications, such as following ovarian surgery, and for trans women using oestrogens under medical supervision.
Health economists warn of recurring shortages of essential medicines. They are calling for more transparent availability reporting, clear prioritisation rules during shortages and better information-sharing between the AEMPS, healthcare practices and pharmacies. This week’s reports show that localised disruptions can quickly have systemic consequences, with an immediate impact on day-to-day healthcare in Spain. elDiario.es was the first to report in detail on the situation and the products affected.
Editor: Clara Simonichek (Article created with AI assistance).